FDA Matters logo
  • Blog
  • About
  • Media
Want More Insights from FDA Matters? Check Out the Q&A Monday Tab for This Subscriber-First Feature

Want More Insights from FDA Matters? Check Out the Q&A Monday Tab for This Subscriber-First Feature

by Steven Grossman | Oct 3, 2025 | Short Takes and Updates

Every Monday, FDA Mtters subscribers receive “Q&A Monday.” They may recirculate, quote from, or reprint it, etc., at their own discretion, which can be particularly useful for media. I do not publicly post the column until the following Monday. You can find past...
Want More Insights from FDA Matters? Check Out the Q&A Monday Tab for This Subscriber-First Feature

What to Expect When You Are Expecting a Shutdown–FDA Edition

by Steven Grossman | Sep 30, 2025 | Short Takes and Updates

I have experienced numerous shutdowns and shutdown threats. Sadly, they have become a familiar part of my DC life. Most often, there is a last-minute deal–whether a 48-hour Continuing Resolution (CR), a week-long CR, or a 6-week CR. No one expects a last-minute...
Want More Insights from FDA Matters? Check Out the Q&A Monday Tab for This Subscriber-First Feature

Weedy Concerns Amidst a Flood of FDA Issues

by Steven Grossman | Sep 26, 2025 | Short Takes and Updates

Flooding the zone has proven to be an extremely effective strategy for the Trump administration. Every day, there are dramatic headlines that I need to ignore to stay focused on the topic that matters most to me, namely the FDA. The flood has been unrelenting. The FDA...
Want More Insights from FDA Matters? Check Out the Q&A Monday Tab for This Subscriber-First Feature

Give Briefings a Chance, Secretary Kennedy

by Steven Grossman | Sep 20, 2025 | Short Takes and Updates

First published in MedPage Today in its Second Opinions columnsOpen minds and expert input are crucial for policymaking….Based on my personal experience, dating back more than 40 years and spanning the administrations of 12 prior HHS secretaries, I can say that Robert...
Want More Insights from FDA Matters? Check Out the Q&A Monday Tab for This Subscriber-First Feature

Advisory Committees, Drug Reviews, and CRL’s. Oh My!

by Steven Grossman | Sep 17, 2025 | Short Takes and Updates

To many of us, advisory committee meetings are emblematic of an FDA that listens, is open to diverse viewpoints, and is willing to change direction when other views prove compelling. FDA never yields the authority to decide. Yet, agency decisions about high-profile...
Want More Insights from FDA Matters? Check Out the Q&A Monday Tab for This Subscriber-First Feature

Short Takes and Updates — September 5, 2025

by Steven Grossman | Sep 5, 2025 | Short Takes and Updates

FDA Matters doesn’t cover the news….we provide analysis of what’s behind the newsThis week: My Comment on Secretary Kennedy’s September 4 Appearance Before the Senate Finance CommitteeMAHA Strategy Plan Likely to Be Released Week of September 8.MAHA...
« Older Entries
Next Entries »

Recent Posts

  • Chairman Cassidy: Please Ask Dr. Overton About FDA Decision-Making
  • The FDA’s Century-Long Campaign to Assure Safe Manufacturing (Part 2)
  • The FDA’s Century-Long Campaign to Assure Safe Drug Manufacturing (Part 1)
  • A Marathon, Not a Sprint: The Long Road to Becoming the Next FDA Commissioner
  • Firing Dr. Makary Solves No Problems….BUT Opens the Door for More Orderly Management and Decision-Making

Recent Comments

No comments to show.
FDA Matters logo

 ©2009-2026 FDA Matters | FDA Matters does not report the news….we provide analysis of what’s behind the news.

We sometimes use artificial intelligence in drafting columns, primarily using Claude AI and Microsoft Co-Pilot. We review and verify all findings, interpretations, and final wording.